Interesting article from the Arthritis Practitioner. Delving into the literature, Ara Dikranian, MD discusses the current thinking on key markers of early disease activity in patients with rheumatoid arthritis (RA), reviews the impact of anti-TNF medications in early RA and assesses the potential of emerging biologic agents.
http://www.arthritispractitioner.com/article/8275Lynn - a terrific link, which I printed for my family practitioners for our next conference of war plans. Thank you. Cathy I like that concept !! ( war plans ) I have to remember that. Sooooo is this our war room to JSNM hmmm......But in a nice, kind, loving way :) Notice - yet again, absolutely no references to all the fabulous research coming out for Minocycline.